Big Moving Stock keep track of the biggest moving stocks in the market.
The Hot Industries
CATV Systems 2
Asset Management 1
The Hot Sectors
CELG Celgene Corporation
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The companys commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The companys pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohns and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales - Analyst Blog25 Jul 2014, 2:56 pmCelgene Beats Q2 Earnings Estimates on Strong Revlimid Sales - Analyst Blog
Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales25 Jul 2014, 12:45 pmCelgene (CELG) reported higher than expected earnings on strong revenues.
Will This Price Target Increase Help Celgene (CELG) Stock Today?25 Jul 2014, 7:31 amNEW YORK (TheStreet) -- Credit Suisse increased its price target on Celgene to $113, increased its estimates through 2016 and set an "outperform" rating. The firm cited the company's new guidance as the reason for the move. The stock was down 0.39% to $85.85 in pre-market trading on Friday. Must Read: Warren Buffett's 25 Favorite Stocks STOCKS TO BUY: TheStreet Quant Ratings has identified a ...
Celgene Stock Falls After Mixed Second-Quarter Earnings24 Jul 2014, 12:33 pmCelgene (CELG) dipped 2.21% to $87.15 in pre-market trading on Thursday after the biotechnology company reported mixed second-quarter results. Click to view a price quote on CELG . Click to research the Drugs industry.
Stock Market News for July 24, 2014 - Market News24 Jul 2014, 9:03 amStock Market News for July 24, 2014 - Market News
Stock Market News for July 24, 201424 Jul 2014, 7:19 amBenchmarks finished mostly higher on Wednesday following upbeat quarterly results from healthcare and technology companies
The Zacks Analyst Blog Highlights: AbbVie, Shire, Gilead Sciences, Sarepta Therapeutics and Celgene17 Jul 2014, 6:12 amThe Zacks Analyst Blog Highlights: AbbVie, Shire, Gilead Sciences, Sarepta Therapeutics and Celgene
Celgene's Otezla fails trial9 Jul 2014, 4:45 pmBig-cap biotech Celgene (CELG) said that its new drug failed a trial for an inflammatory spinal disease, but the stock rebounded from a big drop early Wed. as analysts said the news wasn't a surprise. ...
Two Analysts Don't See Celgene's Weak Trial Results As A Huge Setback9 Jul 2014, 10:37 amShares of Celgene (NASDAQ: CELG ) have been volatile since the company announced weak Phase III trial results for OTEZLA Wednesday morning. The stock was trading in the red during the pre-market session, ...
Jim Cramer's Top Stock Picks: CELG GSAT FCX SBUX2 Jul 2014, 4:18 amSearch Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener. NEW YORK (TheStreet) -- Here are some of the hot stocks Jim Cramer talked about on Tuesday's Mad Money on CNBC: CELG data by YCharts Celgene : Cramer said biotech is back, and his perennial fave Celgene remains at the top of his list of winners. GSAT data by YCharts Globalstar : Cramer said ...